Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

被引:0
作者
Mats Någård
Mei-Lin Ah-See
Karen So
Marit Vermunt
Fiona Thistlethwaite
Mariette Labots
Patricia Roxburgh
Alain Ravaud
Mario Campone
Liselot Valkenburg-van Iersel
Lone Ottesen
Yan Li
Ganesh Mugundu
机构
[1] R&D Clinical Pharmacology and Safety Sciences,Clinical Pharmacology and Quantitative Pharmacology
[2] AstraZeneca,Late Stage Development, Oncology R&D
[3] AstraZeneca,Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D
[4] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences
[5] The Christie NHS Foundation Trust and University of Manchester,undefined
[6] Cancer Center Amsterdam,undefined
[7] Amsterdam UMC,undefined
[8] Beaston West of Scotland Cancer Centre and University of Glasgow,undefined
[9] Bordeaux University Hospital,undefined
[10] ICO – Site René,undefined
[11] Maastricht University Medical Centre,undefined
[12] AstraZeneca,undefined
[13] AstraZeneca,undefined
来源
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词
Adavosertib; Food effect; Pharmacokinetics; Oncology; WEE1;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:97 / 108
页数:11
相关论文
共 107 条
[1]  
Do K(2013)WEE1 kinase as a target for cancer therapy Cell Cycle 12 3159-3164
[2]  
Doroshow JH(2014)The balance between cell cycle arrest and cell proliferation: control by the extracellular matrix and by contact inhibition Interface Focus 4 20130075-560
[3]  
Kummar S(2015)Targeting the DNA damage response in cancer Mol Cell 60 547-4236
[4]  
Gerard C(2012)Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption Mol Cell Biol 32 4226-1677
[5]  
Goldbeter A(1996)Cancer cell cycles Science 274 1672-8217
[6]  
O’Connor MJ(2001)Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator Cancer Res 61 8211-3415
[7]  
Beck H(2015)Phase I study of single-agent AZD1775 (MK-1775), a WEE1 kinase inhibitor, in patients with refractory solid tumors J Clin Oncol 33 3409-4380
[8]  
Nahse-Kumpf V(2016)Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors J Clin Oncol 34 4371-84
[9]  
Larsen MS(2020)Safety, pharmacokinetics, and clinical activity of adavosertib in combination with chemotherapy in asian patients with advanced solid tumors: Phase Ib study Target Oncol 15 75-4544
[10]  
O’Hanlon KA(2017)Molecular pathways: targeting the protein kinase WEE1 in cancer Clin Cancer Res 23 4540-4361